ENTA - エナンタ・ファ―マシュ―ティカルズ (Enanta Pharmaceuticals Inc.) エナンタ・ファ―マシュ―ティカルズ

 ENTAのチャート


 ENTAの企業情報

symbol ENTA
会社名 Enanta Pharmaceuticals Inc (エナンタ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 エナンタ・マシューティカル(Enanta Pharmaceuticals Inc.)は研究開発に集中するバイオテクノロジー企業である。同社は化学主導のアプローチと創薬機能を利用して、ウイルス感染および肝臓疾患の治療分野で小分子薬を作成する。同社の研究開発プログラムは非アルコール性脂肪性肝炎(NASH)/原発性胆道炎(PBC)、呼吸器合胞体ウイルス(RSV)及びB型肝炎ウイルス(HBV)を含む三つの疾患標的に集中する。同社はC型肝炎ウイルス(HCV)に対して直接作用抗ウイルス(DAA)阻害剤のクラスの一員としての新規プロテアーゼ阻害剤を発見した。これらのパリタプレビルおよびグレカププレビル(ABT-493)を含むプロテアーゼ阻害剤はAbbVie Inc. (AbbVie)と共同開発される。同社の製品候補はNASHおよびPBCに対するファルネソイドX受容体(FXR)アゴニスト製品候補及びRSVの臨床候補者であるEDP-938を含む。   エナンタ・ファ―マシュ―ティカルズは、米国のバイオ医薬品会社。感染症分野での小分子薬の作成に焦点を当て、研究開発に注力する。C型肝炎ウイルス(HCV)に対する阻害剤を発見、開発している。主要製品候補は、NS3プロテア―ゼの阻害剤「ABT-450」と多剤耐性菌感染症の治療に開発している二環式の抗生物質「Bicyclolides」である。   Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta's research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV) and emerging coronaviruses, including SARS-CoV-2.
本社所在地 500 Arsenal Street Watertown MA 02472 USA
代表者氏名 Bruce L.A. Carter ブルースL.A.カーター
代表者役職名 Independent Chairman of the Board
電話番号 +1 617-607-0800
設立年月日 1995年
市場名 NASDAQ National Market System
ipoyear 2013年
従業員数 89人
url www.enanta.com
nasdaq_url https://www.nasdaq.com/symbol/enta
adr_tso
EBITDA EBITDA(百万ドル) 110.59200
終値(lastsale) 77.48
時価総額(marketcap) 1501370791.96
時価総額 時価総額(百万ドル) 1510.672
売上高 売上高(百万ドル) 215.34700
企業価値(EV) 企業価値(EV)(百万ドル) 1239.288
当期純利益 当期純利益(百万ドル) 84.84400
決算概要 決算概要 BRIEF: For the nine months ended 30 June 2018 Enanta Pharmaceuticals Inc revenues increased from $26.9M to $139.4M. Net income before extraordinary items totaled $48.3M vs. loss of $18.8M. Revenues reflect Royalties increase from $26.9M to $124.4M Revenue increase from $0K to $15M. Net Income reflects Change in fair value of warrant liabilit increase from $45K (expense) to $41K (income).

 ENTAのテクニカル分析


 ENTAのニュース

   Enanta Pharma FQ3 2022 Earnings Preview  2022/08/07 21:35:00 Seeking Alpha
Enanta Pharma (ENTA) is scheduled to announce FQ3 earnings results on Monday, August 8th, after market close.The consensus EPS Estimate is -$1.39 and the consensus Revenue Estimate…
   Enanta Pharmaceuticals PT Raised to $53 at Oppenheimer  2022/08/01 09:05:01 Investing.com
https://www.investing.com/news/pro/enanta-pharmaceuticals-pt-raised-to-53-at-oppenheimer-432SI-2859079
   Enanta Pharmaceuticals sues Pfizer for patent infringement involving Paxlovid  2022/06/22 18:14:58 Business Journals
The Watertown biotech alleges that the latter drugmaker violated a patent Enanta was awarded earlier this month.
   Enanta Pharmaceuticals Sues Pfizer Over Blockbuster Covid Pill Paxlovid  2022/06/22 15:52:13 Investor''s Business Daily
Shares of ENTA stock jumped Wednesday after Enanta sued Pfizer, claiming Covid pill Paxlovid infringes on its recently won patent.
   Hot Stocks: KFY rises on earnings; ENTA sues PFE over COVID drug; NEWR climbs; DOW downgrade  2022/06/22 15:49:10 Seeking Alpha
KFY rises on earnings; ENTA climbs after suing PFE over a COVID drug patent. NEWR climbs on activist investor interest. DOW drops on a downgrade.
   Enanta Pharmaceuticals PT Raised to $53 at Oppenheimer  2022/08/01 09:05:01 Investing.com
https://www.investing.com/news/pro/enanta-pharmaceuticals-pt-raised-to-53-at-oppenheimer-432SI-2859079
   Enanta Pharmaceuticals sues Pfizer for patent infringement involving Paxlovid  2022/06/22 18:14:58 Business Journals
The Watertown biotech alleges that the latter drugmaker violated a patent Enanta was awarded earlier this month.
   Enanta Pharmaceuticals Sues Pfizer Over Blockbuster Covid Pill Paxlovid  2022/06/22 15:52:13 Investor''s Business Daily
Shares of ENTA stock jumped Wednesday after Enanta sued Pfizer, claiming Covid pill Paxlovid infringes on its recently won patent.
   Hot Stocks: KFY rises on earnings; ENTA sues PFE over COVID drug; NEWR climbs; DOW downgrade  2022/06/22 15:49:10 Seeking Alpha
KFY rises on earnings; ENTA climbs after suing PFE over a COVID drug patent. NEWR climbs on activist investor interest. DOW drops on a downgrade.
   Enanta files patent infringement lawsuit against Pfizer over Paxlovid (NASDAQ:ENTA)  2022/06/22 07:23:27 Seeking Alpha
According to a Lawsuit filed on Tuesday in U.S. District Court for the District of Massachusetts, Pfizer''s blockbuster COVID drug Paxlovid violates biotechnology company…
   ENT and Allergy Associates, LLP and Cooperman Barnabas Medical Center (CBMC) Join Forces to Form a Clinical Affiliation in New Jersey  2022/01/24 16:57:49 Benzinga
Tarrytown, New York, Jan. 24, 2022 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA) is pleased to announce that the practice has formed a clinical affiliation with Cooperman Barnabas Medical Center (CBMC), formerly Saint Barnabas Medical Center. "We are thrilled to affiliate and collaborate with ENT and Allergy Associates. ENTA is recognized throughout the region as a leader providing outstanding care to their patients," states Richard L. Davis, President and CEO, Cooperman Barnabas Medical Center. This affiliation offers New Jersey residents access to enhanced otolaryngology and allergy healthcare services across a wide variety of specialties and sub-specialties, provided by CBMC. ENTA plans to integrate its NextGen Electronic Health Records system with CBMC to create a single button protocol that will help quickly and efficiently coordinate care between physicians and facilities. Patients who are found to need tertiary care will be quickly seen by the specialist within 48 hours.
   Enanta under pressure after SVB Leerink slashed price target  2022/01/13 17:58:51 Seeking Alpha
The shares of Enanta Pharmaceuticals <> dropped for the third straight session to reach over a three-month low after SVB Leerink cut its price target, highlighting the concerns on
   Enanta Pharmaceuticals rises on pipeline updates for 2022  2022/01/06 19:48:41 Seeking Alpha
Enanta Pharmaceuticals <> provided updates on its pipeline and said President and CEO Jay Luly will shed light on the virology programs and plans for 2022 at the 40th Annual J.P
   Contrasting Mallinckrodt (OTCMKTS:MNKKQ) and Enanta Pharmaceuticals (NASDAQ:ENTA)  2021/12/18 16:08:41 Dakota Financial News
Mallinckrodt (OTCMKTS:MNKKQ) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership and valuation. Analyst Ratings This is a summary of recent recommendations for Mallinckrodt and Enanta Pharmaceuticals, as reported []
   $25.86 Million in Sales Expected for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) This Quarter  2021/12/13 09:30:42 Dakota Financial News
Equities research analysts expect Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to announce sales of $25.86 million for the current quarter, according to Zacks. Three analysts have provided estimates for Enanta Pharmaceuticals earnings. The highest sales estimate is $30.26 million and the lowest is $19.61 million. Enanta Pharmaceuticals posted sales of $31.74 million in the same quarter last []

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 エナンタ・ファ―マシュ―ティカルズ ENTA Enanta Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)